Sirius Therapeutics appoints Dr. Qunsheng Ji CEO and to the Board of Directors

August 7, 2022, Shanghai, China, and San Diego, the United States – Sirius Therapeutics today announced the appointment of Dr. Qunsheng Ji as its Chief Executive Officer and Executive Board Director. Dr. Ji, a renowned leader in global new drug development, has over 30 years of experience in drug development and business management in the industry. Previously, he has served as Vice President and Head of Oncology and Immunology at WuXi AppTech; Head of Bioscience, Asia and Emerging Market iMed at AstraZeneca; and Director of Translational Medicine at AstraZeneca’s Innovation Center in China.

About Sirius Therapeutics

Sirius is an innovative biotech company developing novel RNAi therapies for global markets. We are dedicated to providing solutions for physicians and patients to manage cardiovascular diseases. Our aim is to be a leading developer of RNAi therapeutics for the management of chronic diseases.

After founding in 2021, Sirius established an innovation, research and development center in the United States and a translational center in China to address unmet patient needs in chronic disease.  Leveraging RNAi technology, we offer a portfolio of solutions for patients to change the future of cardiovascular disease.